Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710423 | 0.86 | ALDH1A1 (0.37) | PKMALDH1A1POLBNSD2HDAC3 | |
| SCHEMBL6834072 | 0.84 | ALDH1A1 (0.41) | PKMALDH1A1ALBNSD2MEN1 | |
| SCHEMBL6707676 | 0.84 | ALDH1A1 (0.36) | PKMALDH1A1POLBNSD2HDAC3 | |
| SCHEMBL6834504 | 0.84 | LMNA (0.47) | PKMALDH1A1ALBMEN1KMT2A | |
| SCHEMBL6830151 | 0.84 | ALB (0.42) | ALBPOLBNSD2NR1H4KMT2A | |
| SCHEMBL6833157 | 0.84 | PARP14 (0.42) | PKMALDH1A1ALBPOLBNSD2 | |
| SCHEMBL6830741 | 0.84 | ALDH1A1 (0.47) | ALDH1A1ALBPOLBNSD2HDAC3 | |
| SCHEMBL6830655 | 0.83 | ALB (0.43) | ALDH1A1ALBPOLBNSD2NR1H4 | |
| SCHEMBL6833910 | 0.82 | KDM4E (0.45) | PKMALDH1A1ALBPOLBNSD2 | |
| SCHEMBL6833897 | 0.82 | ALB (0.42) | PKMALBPOLBNSD2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | PKM 3785/4885ALDH1A1 170/4885ALB 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.